Drug Trial Radar · NCT03525600
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
Aug 31, 2018
Primary completion
Jun 21, 2021
Study completion Jun 20, 2022
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
Conditions
- Geographic Atrophy
Interventions
APL-2Drug
Complement (C3) Inhibitor
APL-2Drug
Complement (C3) Inhibitor
Sham ProcedureOther
Subjects will receive a Sham procedure every month
Sham ProcedureOther
Subjects will receive a Sham procedure every other month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12Time frame: Baseline (screening) and Month 12
Locations
141 sites in 15 countries. Site status is shown where the registry gives one.
Retinal Research Institute
Phoenix, Arizona
Associated Retina Consultants, Ltd
Phoenix, Arizona
Retina Institute of California dba Acuity Eye Grp
Arcadia, California
California Retina Consultants
Bakersfield, California
Retina Vitreous Associates Medical Group
Beverly Hills, California
The Retina Partners
Encino, California
The Gavin Herbert Eye Institute/UC Irvine
Irvine, California
Northern California Retina Vitreous Associates
Mountain View, California
Retina Institute of California Medical Group
Palm Desert, California
Byers Eye Institute at Standford, Stanford School of Medicine
Palo Alto, California
Retina Consultants San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
California Retina Consultants
Santa Barbara, California
Bay Area Retina Associates
Walnut Creek, California
Danbury Eye Physicians & Surgeons, P.C. - Danbury
Danbury, Connecticut
New England Retina Associates
Hamden, Connecticut
Retina Group of New England,PC
Waterford, Connecticut
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida
Pinnacle Research Institute
Fort Lauderdale, Florida
Retina Health Center
Fort Myers, Florida
Bascom Palmer Eye Institute
Palm Beach Gardens, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
East Florida Eye Institute
Stuart, Florida
Southern Vitreoretinal Associates
Tallahassee, Florida
Retina Associates of Florida
Tampa, Florida
University of South Florida (USF) Eye Institute
Tampa, Florida
Southeast Retina Center, PC
Augusta, Georgia
Georgia Retina
Marietta, Georgia
Midwest Eye Institute
Indianapolis, Indiana
Sabates Eye Center
Leawood, Kansas
Elman Retina Group, PA
Baltimore, Maryland
Cumberland Valley Retina Consultants, PC
Hagerstown, Maryland
Mid Atlantic Retina Specialists
Hagerstown, Maryland
Retina Specialists
Towson, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
New England Retina Consultants, PC
Springfield, Massachusetts
Associated Retinal Consultants, P.C
Grand Rapids, Michigan
Retina Specialists of Michigan / Foundation for Vision
Grand Rapids, Michigan
Retina Consultants of Michigan
Southfield, Michigan
Associated Retinal Consultants PC
Traverse City, Michigan
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.